Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Akebia Therapeutics

Akebia Therapeutics

A company developing Hypoxia Inducible Factor therapies to treat kidney diseases and other conditions

All edits by  Sameeha Sulaiman 

Edits on 12 Feb, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 12 Feb, 2019
Edits made to:
Article (+746 characters)
Table (+7 rows) (+14 cells) (+271 characters)
Article

The company's lead product candidate is Vadadustat, a hypoxia inducible factor (HIF) stabilizer that inhibits the prolyl hydrolase (PH) enzyme. It is in Phase 3 of clinical development for patients with renal anemia. Vadadustat is designed to mimic the body's adaptive response to hypoxia, such as that experienced at moderate altitude. The drug is currently an investigational drug and has not yet been approved by the US FDA or any other regulatory authority.

Akebia is developing other HIF-based portfolio of product candidates that target serious diseases of high unmet need. This includes those developed internally as well as in-licensed products.

In December 2018, Akebia merged with Keryx Biopharmaceuticals under the former company's name.

Table

Name
Role
Related Golden topics

Jason Amello

Senior VP & CFO

John Butler

President & CEO

Karen Tubridy

Senior VP & Chief Development Officer

Michael Dahan

Senior VP & Chief Business Officer

Nikki Hadas

Senior VP & General Counsel

Edits on 9 Jan, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 9 Jan, 2019
Edits made to:
Infobox (+3/-3 properties)
Article (+199 characters)
Table (-1 rows) (-2 cells) (-22 characters)
Table (+1 rows) (+4 cells) (+184 characters)
Article

Akebia Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts. It is focused on the development and commercialization of therapeutics for patients with chronic kidney disease.

Table

Name
Role
Related Golden topics

Mike Venerable

Investor

Table

Title
Author
Link
Type

Akebia Therapeutics Shareholders Approve Merger with Keryx

BusinessWire

Web

Infobox
Golden logo
By using this site, you agree to our Terms & Conditions.